1.49BMarket Cap-0.73P/E (TTM)
47.250High42.840Low1.60MVolume44.270Open43.110Pre Close71.68MTurnover4.72%Turnover RatioLossP/E (Static)33.89MShares63.99052wk High0.59P/B1.49BFloat Cap12.33052wk Low--Dividend TTM33.89MShs Float63.990Historical High--Div YieldTTM10.23%Amplitude12.330Historical Low44.788Avg Price1Lot Size
Grail Stock Forum
GRAL gained 18.3% to $56.50 shortly before 4:30 p.m. ET after reporting $38.3 million in revenues, reportedly beating the $34.4 million that analysts expected. The company also narrowed its loss per share to $2.89 from $6.04 in the same period last year.
CEO Bob Ragusa called 202...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet